Submission to the College of Physicians and Surgeons of Ontario Regarding Professional Obligations and Human Rights

Concerns about the integrity of Dr. Melissa Toyos' marketing for Verteporfin treatment, suggesting photos may be digitally altered. Users express skepticism about the treatment's promotion and results.

A 30-year-old female with PCOS and male pattern baldness is frustrated with her endocrinologist's recommendation of only Spironolactone and minoxidil, feeling that dutasteride, finasteride, and progesterone would be more effective. Other users suggest various online sources for treatments, warn against self-medicating due to potential risks, and recommend seeking a specialized endocrinologist or considering additional treatments like Inositol, Berberine, and dermaneedling.

A user from Ontario, Canada, is seeking cheaper options for topical Minoxidil and oral Finasteride for hair loss, as current prices are around $300 for a three-month supply. They are asking if this pricing is typical and if there are more affordable alternatives.

A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

The conversation is about a user preparing to join the ABS-201 clinical trial for hair loss treatment, which involves a prolactin inhibitor. The user plans to update others on their progress if enrolled.

Minoxidil alone is not effective for significant hair regrowth; combining it with finasteride or dutasteride is necessary. Additional treatments like hair transplants, microneedling, or oral medications are recommended for better results.